Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 7/20 | 0.40 |
| ▸ | THRA | P10827 | 3/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.36 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6861552 | 0.93 | THRB (0.40) | THRBTHRAALDH1A1GAAPKM | |
| SCHEMBL6861917 | 0.93 | THRB (0.41) | THRBTHRAHSD11B1EPHX1EPHX2 | |
| SCHEMBL6861848 | 0.87 | THRB (0.42) | THRBTHRAHSD11B1POLBHSD17B3 | |
| SCHEMBL1640543 | 0.81 | THRA (0.51) | THRBTHRA | |
| SCHEMBL4961949 | 0.81 | POLB (0.43) | THRBTHRAHSD11B1POLBHSD17B3 | |
| SCHEMBL4961754 | 0.81 | GAA (0.41) | THRBTHRAPOLBALDH1A1GAA | |
| SCHEMBL7592718 | 0.81 | SOS1 (0.47) | THRBTHRAPOLBALDH1A1GAA | |
| SCHEMBL7061428 | 0.80 | THRA (0.50) | THRBTHRAHSD17B3HSD17B2 | |
| SCHEMBL1641051 | 0.79 | THRA (0.65) | THRBTHRAEPHX1EPHX2 | |
| SCHEMBL6658204 | 0.79 | THRA (0.59) | THRBTHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020045751-A1 | Thyromimetic organic compounds | NOVARTIS AG (CH) | 2002-04-18 | — | — | US | claimed |
| US-6790978-B2 | 4-HYDROXY-3-ARYLSULFONYL, 3-AMINOSULFONYL OR 3-AMINOCARBONYL-PHENOXYANILINOCARBONYL-OPTIONAL ALKYLENE-CARBOXYLIC ACID OR CARBONYL-5-TETRAZOLES | NOVARTIS AG (CH) | 2004-09-14 | — | — | US | disclosed |
| US-20020045751-A1 | Thyromimetic organic compounds | NOVARTIS AG (CH) | 2002-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045751-A1 | Thyromimetic organic compounds | TPO, THRA, LPO | THRB 7/4885THRA 2/4885HSD11B1 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.